Tissue factor (TF), the cell surface receptor and cofactor for factor Vlla (FVlla), is considered the major physiologic trigger of the coagulation cascade. Most monoclonal antibodies to TF have been reported to inhibit TF activity by blocking association of FVll(a) with TF. Using solution-phase kinetic analyses, we have reexamined two strongly inhibitory anti-TF monoclonal antibodies (TF8-11D12 and TF9-9C3) previously reported to block FVll binding in cell-binding assays. Kinetic analysis of TF9-9C3 was consistent with direct competition with FVlla for binding to TF. However, antibody TF8-llD12 did not block FVlla binding to TF as measured by ability of the ISSUE FACTOR (TF), considered to be the primary T triggering agent of the coagulation cascade, binds the serine protease factor VIIa (FVIIa) with high affinity and functions as its essential FVIIa bound to TF then activates factors IX (FIX) and X (FX) via limited proteoly~is.~ FVII normally circulates in plasma predominantly as the inactive zymogen but can be converted to FVIIa by a variety of proteases, including FIXa, FXa, FXIIa, and t h r~m b i n .~-~ TF accelerates this process, ensuring that TF-bound FVII is preferentially converted to FVIIa.5-7 FVII has been reported to undergo autoactivation in the presence of certain artificial, positively charged surfaces.8 Interestingly, TF has recently been shown to promote FVII autoactivation or, more precisely, TFmediated activation of FVII by FVIIa.9 Studies of soluble mutant T F suggest that TP-mediated FVII autoactivation may be an important and, possibly essential, initial step in triggering the clotting cascade.l0
T triggering agent of the coagulation cascade, binds the serine protease factor VIIa (FVIIa) with high affinity and functions as its essential FVIIa bound to TF then activates factors IX (FIX) and X (FX) via limited proteoly~is.~ FVII normally circulates in plasma predominantly as the inactive zymogen but can be converted to FVIIa by a variety of proteases, including FIXa, FXa, FXIIa, and t h r~m b i n .~-~ TF accelerates this process, ensuring that TF-bound FVII is preferentially converted to FVIIa.5-7 FVII has been reported to undergo autoactivation in the presence of certain artificial, positively charged surfaces.8 Interestingly, TF has recently been shown to promote FVII autoactivation or, more precisely, TFmediated activation of FVII by FVIIa.9 Studies of soluble mutant T F suggest that TP-mediated FVII autoactivation may be an important and, possibly essential, initial step in triggering the clotting cascade.l0
Monoclonal antibodies against TF have been useful for purification of humanl1J2 or bovine TF13 and also as molecular probes for studying the interaction of TF with FVIIa.11J4- 16 The vast majority of anti-TF monoclonal antibodies inhibit TF procoagulant activityl1J3J4 and, in those cases tested, reportedly block the association of FVII with T F . I 3 -l 6 Typically, evaluation of the effect of such antibodies on TF procoagulant activity has involved preincubation of TF with IgG before the addition of plasma or FVIIa.13J4 Ruf and Edgingto@ recently reported that although several anti-TF monoclonal antibodies were potent inhibitors of TF activity in such assays, the effect required preincubation of antibody with T F unless extremely high concentrations of IgG were employed. Thus, these antibodies were poor inhibitors of TF clotting activity when included in plasma, probably because the rate of association of antibody with T F was slower than that of FVII with TF. However, one antibody (TF8-5G9) was unusual in being a potent inhibitor of TF function when included in plasma and, therefore, did not require preincubation with TF.l6 The mechanism of action of TF8-5G9 was not addressed in detail by Ruf and Edgington,16 although they proposed that TF8-5G9 had multiple functions, both inhibiting 1251-FVII binding to cell surfaces and also inhibiting TF function more rapidly than could be accounted for by dissociation of 1251-FVII previously bound to cells. The ability of TF8-5G9 to inhibit TF procoagulant activity TF:FVlla complex to cleave a small peptide substrate or by enhanced reactivity of FVlla with a tripeptidyl-chloromethylketone. Interestingly, TF8-11D12 strongly inhibited cleavage of all three known macromolecular substrates (factors VII, IX, and X) of the TF:FVlla complex. We hypothesize that TF8-11 D12 blocks access of macromolecular substrates to the active site of Wlla by steric hindrance. This study identifies a useful probe for TF function and provides insights into the inhibitory mechanism of an unusual class of antibody proposed for therapeutic intervention in thrombotic disease. rapidly has led to the proposal that it may be especially advantageous for therapeutic intervention of TF-mediated thrombotic diseases,l6 and preclinical studies of this antibody in chimpanzees have been initiated.l7
In this study, we report an analysis of the mechanism of action of the anti-TF antibody TF8-llD12, which shares a common epitope with TF8-5G9. Using solution-phase enzyme kinetic analyses, we have found that TF8-llD12 did not block binding of FVIIa to TF as measured by catalytic activity of the TF:FVIIa complex toward a small chromogenic peptide substrate or by susceptibility of the TF:FVIIa complex to inhibition by a peptidylchloromethylketone. However, TF8-llD12 strongly inhibited the ability of the TF:FVIIa complex to activate three serine protease zymogens: FVII, FIX, and FX. Therefore, our studies suggest that TF8-llD12 acts by specifically blocking access of macromolecular substrates to the formed complex of TF and FVIIa rather than blocking binding of FVIIa to TF or altering the catalytic center of bound FVIIa.
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bovine phosphatidylserine and phosphatidylcholine were purchased from Matreya (Pleasant Gap, PA).
Human FIX and FX were purified from plasma as d e s~r i b e d .~~* '~ Human plasma FVII was purified by immunoaffinity chromatography and activated to FVIIa as described.l0 Recombinant human FVII was produced in 293 cells and purified by immunoaffinity chromatography as described.1° Human TF was purified from brain by immunoaffinity chromatography as described12 except that antibody TF9-5B7 was used in place of TF8-5G9.14 TF was reconstituted into phospholipid vesicles containing PS:PC (phosphatidy1serine:phosphatidylcholine 50:50) by the method of Carson and Konigsberg." Phospholipid vesicles without TF were prepared in the same manner but substituting bovine serum albumin for TF. Alternatively, TF was reconstituted into pure phophatidylcholine (PC) vesicles according to the method of Mimms et al?' Concentrations of relipidated TF are reported as half the actual concentration, assuming random orientation of TF (50% molecules oriented toward the outside) as reported by Bach et A soluble mutant form of TF lacking the transmembrane and cytoplasmic domains was expressed in Escherichia coli and will be described in detail elsewhere (A. Rezaie, M. Fiore, P. Neuenschwander, C. Esmon, and J. Morrissey, in press). Briefly, a truncated TF complementary DNA (cDNA) clone encoding amino acids 2 through 219 (numbered according to Morrissey et al' ) was cloned into an expression vector containing the leader peptide from the pelB gene of Enoinia c a r o t o~o r a~~ to direct the expressed protein to the periplasmic space. Immediately following the leader peptide is a sequence encoding a dodecapeptide epitope for the calcium-dependent monoclonal antibody HPC4.= The result is the expression of a fusion protein consisting of the truncated, soluble form of TF ( s T F~.~~~) with the HPC4 epitope fused to its N-terminus. Bacterially expressed sTF2.219 is equivalent to, and displayed the same cofactor activity as, soluble truncated TF (sTF1.219) expressed in mammalian cells (A. Rezaie, M. Fiore, P. Neuenschwander, C. Esmon, and J. Morrissey, in press).
Anti-TF monoclonal antibodies were purified from ascites fluid by affinity chromatography on immobilized protein A as previously described.14 Purified IgG was biotinylated using NHS-LC-biotin (Pierce, Rockford, IL). Purified HPC4 monoclonal antibody IgGZ was a gift from Dr Charles Esmon (Oklahoma Medical Research Foundation, Oklahoma City). Fab fragments of monoclonal antibodies were prepared using a commercially available kit (Immunopure Fab, Pierce; performed according to the manufacturer's directions) in which purified IgG was digested with immobilized papain followed by use of immobilized protein A to remove Fc fragments and uncleaved IgG. Polyacrylamide gel electrophoretic analysis of the final product indicated lack of detectable contaminating Fc and IgG by Coomassie staining.
STF2.219 (10 pg/mL) in TBS (30 mmol/L Tris HC1, pH 7.4,O.l mol/L NaCI, 0.02% sodium azide) was coated onto multiwell plates overnight at 4°C and nonspecific binding was blocked by treatment with 5% nonfat, dried bovine milk in TBS for 2 hours at 37°C. After washing three times with TBS, wells were incubated with a mixture of biotinylated TFS-5G9 IgG (0.1 pg/mL) and competitor IgG (20 pg/mL) in TBSA/Triton (0.1% bovine serum albumin, 0.1% Triton in TBS) for 2 hours at 37°C and then washed three times with TBS. Wells were incubated for 30 minutes at 37°C with streptavidin-conjugated alkaline phosphatase (0.12 pg/mL) in TBSA/Triton and washed three times with TBS. Hydrolysis of p-nitrophenylphosphate substrate (1 mg/mL) was monitored at 405 nm.
Measurement of FVIIa amidolytic activity. Measurement of FIX activation.
where i is the Y-intercept (initial absorbance at 405 nm), m is the initial slope of the curve (level of FXa present at t = 0), and C is the quadratic constant (rate of change of the slope) that is directly related to the rate of FXa generation, and hence the concentration of FIXa in the sample. Although C is a complex constant, consisting of both a term for the rate of cleavage of chromogenic substrate by FXa, as well as a first-order rate constant for cleavage of FX by FIXa, changes in C almost exclusively reflect changes in the latter first-order rate constant, under the conditions used experimentally that yield low levels of FXa?6 Therefore, for the purpose of these studies, the determined value of C for each sample was used to determine FIXa concentrations (in nanomoles per liter) by comparison with a standard line of FIXa versus C, prepared using known concentrations of purified FIXa in the above assay. The measured response was linear well above all levels of FIXa detected in the experiment and yielded a slope of 0.37 mOD/min2 per nanomolar FIXa.
Activation of lzI-FVII to 1251-FVIIa by the TF:FVIIa complex was followed as described.l0 In short, 30 nmol/L TF reconstituted in PC vesicles was mixed with 5 mmol/L CaC12 in TBSA and allowed to incubate at 37°C for 45 minutes in the presence or absence of the indicated antibody (3 p,mol/L). Activation of 1251-FVII was initiated by the simultaneous addition of FVIIa and 1251-FVII to 5 and 25 nmol/L, respectively. Timed samples were removed from the reaction into an equal volume of gel-sample loading buffer (0.125 mol/L Tris HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mmol/L DTT, 0.05% bromophenol blue), boiled for 5 minutes, and then electrophoresed on 12% polyacrylamide slab gels. The radioactivity in dried gels was quantitated using a radioanalytic imaging system (AMBIS Systems Inc, San Diego, CA). Initial rates of lzI-FVII activation (percent total radioactivity per minute) were estimated by fitting activation data with a first-order exponential equation as described. 
where VZZa, is the initial FVIIa concentration, VZZa, is the residual FVIIa concentration (activity) at any time, t, and k is the p s e u d e first-order rate constant for decay of FVIIa activity. Apparent dissociation constants (kd) were obtained by fitting the appropriate titration data directly with the equation
Determination of binding constants.
(3) where WZa, and TF, are the initial levels of FVIIa and TF, and Vmux refers to the maximum velocity obtainable upon saturation of FVIIa with TF. This quadratic form of a binding isotherm has previously been used for the kinetic examination of several enzyme-cofactor interaction^^^.^^ and is required for analyzing titration data under conditions in which neither component can be held at limiting levels compared to the dissociation constant being determined. In the present case, where relatively high levels of FVIIa were required experimentally, any changes in the concentration of added (free) TF, as a result of binding to nonlimiting levels of FVIIa, were accounted for by using this equation. Fits to equation 2 were obtained by holding VZZa, constant (at its known experimental concentration) during the fitting procedure. All linear and nonlinear regression procedures were those of Marq~a r d t ?~ as described by Bevington?O using data analysis software written and kindly provided by Dr Jolyon Jesty of the State University of New York at Stony Brook, NY.
RESULTS
Effect of anti-TF monoclonal antibodies on the amidolytic activity of the TF:FUZa complex. Upon binding of FVIIa to either relipidated human TF or soluble mutant TF, the amidolytic activity of FVIIa toward the chromogenic peptide substrate Spectrozyme fXa is enhanced.31 In the present study, this was exploited to quantitate the degree of productive binding of FVIIa to TF. In a typical experiment, a fixed concentration of FVIIa was titrated with increasing concentrations of TF in the presence or absence of a large excess of purified anti-TF antibody. Surprisingly, although the anti-TF antibody TF8-llD12 had previously been shown to inhibit TF procoagulant activity strongly,14 it did not inhibit T F function at all in this assay (Fig 1A) . Thus, near-identical titration curves were observed in the presence or absence of TF8-llD12, although at saturating concentrations of TF, the plateau in amidolytic activity of the TF:VIIa complex was slightly higher in the presence of TF8-11D12 IgG compared with the control titration in the absence of the antibody. FVIIa was, therefore, capable of productively binding to TF even in the presence of a concentration of TF8-llD12 IgG more than sufficient to totally block FX activation (described below).
When the titration data of Fig 1C) .
To further examine possible effects of TF8-llD12 on TF-induced changes in the catalytic center of FVIIa, the kinetics of incorporation of the chloromethylketone inhibitor FFRck into the active site of FVIIa were examined (Fig  2) . FFRck was previously shown to react with free FVIIa?2 Given the increased amidolytic activity of FVIIa upon binding to TF, we hypothesized that the reactivity of the active site histidine in FVIIa might likewise be enhanced when FVIIa bound to TF. Indeed, the rate of inactivation of FVIIa by FFRck in the presence of sTF2.219 (0.10 & 0.02/ min) was almost sevenfold higher than in its absence (0.015 f 0.004/min). Inclusion of TF8-llD12 had no signif- Antibody TF9-9C3 was included in these studies as an example of an anti-TF antibody that has blocked TF function in all assay modes we have examined. In contrast to TF8-llD12, TF9-9C3 completely abolished the TFmediated increase in FVIIa amidolytic activity at all concentrations of TF or s T F~.~~~ tested (Fig 1) . To determine the mode of inhibition by TF9-9C3, experiments were performed in which a fixed concentration of TF was titrated with TF9-9C3 in the presence of three different concentrations of FVIIa. Dixon plots of the resulting data were consistent with competitive inhibition, with a K, (inhibitor constant) for TF9-9C3 of 2.5 ' . 0.1 nmol/L (Fig 3) . Competition between anti-TF antibodies for binding to TF. Another inhibitory anti-TF antibody, TF8-5G9,14 was found to share the same unusual property with TF8-llD12 of not blocking FVIIa binding to TF, as determined kinetically (Fig lA, calculated kd for FVIIa binding to TF in the presence of TF8-5G9 was 0.19 ? 0.02 nmol/L). To test if TF8-llD12 and TF8-5G9 bound to similar or distinct epitopes on TF, competition studies were performed in which an excess of a given unlabeled IgG was used as a potential competitor for binding of biotinylated TF8-5G9 to immobilized s T F z -~~~ in an ELISA (Table 1) . TF8-llD12 effectively competed agaisnt TF8-5G9 binding, whereas TF9-10H10, a noninhibitory anti-TF monoclonal antibody (MAb) whose epitope was previously reported to overlap that of TF8-5G9,15 partially inhibited binding of TF8-5G9 in this assay. TF9-9C3, on the other hand, did not compete at all with TF8-5G9 for binding to TF. Thus, TF8-5G9 and TF8-llD12 bound to identical or overlapping epitopes on TF, which were completely distinct from the epitope for Effect of anti-TF antibodies on activation of FXand FIX by the TF:FVZZa complex. Although antibody TF8-llD12 was previously reported to inhibit the procoagulant activity of T F strongly,14 the data presented above indicate it has no effect on the affinity of FVIIa for wild-type TF, nor does it inhibit TF cofactor function as measured by enhancement of FVIIa amidolytic activity. To examine this apparent discrepancy further, the effect of TF8-llD12 on the rate of activation of FX and FIX, two natural macromolecular substrates for TF.FVIIa, was examined. TF8-llD12 IgG abolished formation of FXa by the S T F~.~~~: F V I I~ complex, whereas a control IgG at the same concentration had no effect (Fig 4A) . Antibody TF9-9C3 also blocked activation of FX (data not shown), which is consistent with the ability to block binding of FVIIa to TF demonstrated above. TF8-llD12 treatment of relipidated, wild-type TF similarly abolished FX activation (data not shown). In addition, incubation of TF with Fab fragments of TF8-11D12 also abolished FX activation, except that the concentration of half-maximal inhibition by the Fab was 10-fold higher than by the intact IgG (data not shown).
The TF:FVIIa complex has been shown to activate FIX as well as FX,33 but the ability of the S T F~.~~~: F V I I~ complex to activate FIX has not previously been reported. FIX activation by S T F~.~~~: F V I I~ was measured in a two-stage assay in which FIX was first incubated with s T F~-~~~, FVIIa, and phospholipid vesicles to generate FIXa. The second TF9-9C3. stage was modified after Griffith et a1,26 in which quenched timed samples were incubated with polylysine (which serves as a synthetic cofactor for FIXa), FX, and chromogenic FXa substrate. TF8-llD12 IgG or Fab completely blocked FIXa generation, as did TF9-9C3, whereas the negative control antibody was without effect (Fig 4B) .
Antibody inhibition of FWI autoactivation. The ability of antibody TF8-llD12 to inhibit FVII autoactivation was examined by preincubating relipidated TF with IgG, then adding a mixture of *251-FVII (25 nmol/L final concentration) and unlabeled FVIIa (5 nmol/L final concentration). At various times samples were removed, quenched, and subjected to SDS-PAGE followed by autoradiography to visualize the TF-mediated conversion of single-chain lZ5I-FVII to two-chain lZI-FVIIa (Fig 5) . Preincubation of TF with either TF9-9C3 or TF8-llD12 significantly reduced the observed rate of lZI-FVII activation from 11.4%/min with no added antibody to 0.17%/min and 1.12%/min for TF9-9C3 and TF8-11D12, respectively. The use of an irrelevant antibody (HPC4) as a negative control had comparatively little effect (6.3% /min).
DISCUSSION
In a previous study characterizing a panel of 24 monoclonal antibodies, all but one of the antibodies were found to inhibit the clotting activity of TF, as well as to inhibit specific binding of lZ5I-FVII to 582 ~e1ls.l~ It was therefore concluded that the inhibitory antibodies blocked association of FVII(a) with TF.14 In this study, we have demonstrated that, surprisingly, the inhibitory antibody TF8-llD12 did not diminish TF cofactor function as measured by enhancement of the amidolytic activity of FVIIa toward a small peptide substrate or by enhancement of reactivity of FVIIa toward a peptidyl-chloromethylketone inhibitor. Interestingly, the derived kd values for binding of FVIIa to TF were essentially unchanged in the presence of TF8-llD12 IgG at antibody concentrations more than sufficient to block FX activation totally. These results indicate that TF8-11D12 does not compete with FVIIa for binding to TF, nor does it block the presumed change in the catalytic center of FVIIa upon binding to TF.
Antibody TF8-llD12 may be identical to TF8-5G9, an antibody derived from the same fusion14 that has been the In a recent study using treatment of living 582 cells with antibody TF8-3.39, Ruf and Edgington16 reported that the antibody at 50 nmol/L raised the apparent KM (Michaelis constant) for FX, whereas another inhibitory anti-TF antibody did not. Both antibodies also dccreased the apparent Vmax in the prcsence of 0.2 nmol/L FVIIa, but this effect was essentially overcome by increasing the FVIla concentration to 5 nmol/L. In a separate study from the same laboratory, 50 nmol/L anti-TF IgG was more than sufficient to totally abolish detectable binding of 5 nmol/L 'L51-FVII to 582 cells.Is Furthermore, both TF8-llD12 and TF8-5G9 were initially reported to block specific binding of 1L51-FVII to the surface of 582 cells.14 In contrast to these 582 cell-binding studies, in the present study, we found that saturating lcvels of TMI-I 1 D12 IgG had no significant effcct on binding of FVIIa to wild-typc TF in PS:PC or pure PC vesicles. The lack of effect of TF8-llD12 was not due to lack of antibody binding because under the same conditions complete blockage of the activation of FIX or FX was observed. Therefore, we conclude that although TF8-llD12 caused a minor perturbation in the aninity of ~TFz.2~9 for binding to FVIIa, the antibody had no cffect on thc affinity of FVIIa for wild-type TF and therefore did not compete with FVIIa for binding to TF. In contrast, another inhibitory anti-TF antibody, TF9-9C3. blocked the TFmediated increase in FVlIa amidolytic activity. Dixon plots wcrc consistent with direct competition between FVIIa and TF9-9C3 for binding to TF.
A potential explanation for the apparent discrepancy between thc lack of inhibition of FVIIa binding to purified TF in phospholipid vesicles by TF8-11D12, and previous studies using 582 cells, is that the previous binding studies used multiple wash steps and were therefore not pcrformed strictly at c q~i l i b r i u m .~~.~~~~~~ Thus, perturbations by the antibodies of the dissociation rate of FVlIa from TF might be reflected in a decrease in the measured specific binding of lL51-FVII to 582 cells. Another potential explanation is the conversion of cell-bound FVlI to FVIIa via autoactivation: a process that was found to be inhibited by TF8-11D12. In addition, it is possible that the presentation ofTF on the surfacc of 582 cells differs from that of purified TF reconstituted into PS:PC vesicles, and it is also possible that the antibody may have a differential effect on binding of FVII versus FVlIa.
The TFAVIIa complex has three known protein sub- strates: FX, FIX, and FVII.47 TF8-llD12 was found to abolish the activation of both FIX and FX by the TF:FVIIa complex, and it was also found to inhibit the autoactivation of FVII mediated by TF. Therefore, we conclude that the anticoagulant mechanism of TF8-llD12 is via blocking the cleavage of macromolecular substrates by the TF:FVIIa complex, whereas having essentially no effect on the association of FVIIa with wild-type TF. The consequence of this mode of inhibition is that the antibody will inhibit conversion of FVII to FVIIa, as well as directly inhibit the ability of TF:FVIIa to activate FIX or FX.
Steric hindrance of macromolecular substrate binding by the relatively bulky IgG molecule is a likely explanation for this phenomenon. It is also possible that the epitope for TF8-llD12 directly overlaps a substrate binding site on TF necessary for recognition and cleavage of macromolecular substrates, especially because Fab fragments of TF8-llD12 showed the same effect as intact IgG. However, this does not necessarily rule out the steric hindrance hypothesis, because even Fab fragments are larger than TF. Clearly, the active site of FVIIa is not completely occluded by these antibodies, nor is the TF-induced change in the active center of FVIIa abrogated, because TF retains normal cofactor function toward FVIIa (measured by amidolytic activity) in the presence of these antibodies.
Because almost all of the enzymatic steps of the clotting cascade occur on the cell surface, it has been proposed that one of the functions of the protein cofactors of the coagulation proteases is to position the active site of the enzyme at the optimal distance from the membrane surface for attack on the activation peptide of the cognate protein substrate, which also binds to the phospholipid Therefore, an additional explanation for the selective effect of TF8-11D12 on activation only of macromolecular substrates could be that binding of the antibody reorients the TF: FVIIa complex such that the active site is no longer positioned at the optimum distance relative to the membrane surface. However, the fact that the antibody had essentially the same effect on soluble sTF2.219:FVIIa complexes in the absence of phospholipids argues against this hypothesis.
The class of anti-TF antibody exemplified by TF8-5G9 and TF8-llD12 has been proposed to be especially advantageous for therapeutic intervention of TF-mediated thrombotic disorders, because it could inactivate the TF:FVIIa complex rapidly prior to dissociation of bound FVIIa. 16 The present study provides insights into the mechanism of action of this unusual type of anti-TF antibody. It also demonstrates that TF8-11D12 represents a potentially valuable reagent for specifically probing the structure/ function relationship of TF. For personal use only. on November 15, 2017. by guest www.bloodjournal.org From
